Natural Strategies for Stopping a Common Energy Drain in ME/CFS and Fibromyalgia

By Jacob Teitelbaum, MD

www.ProHealth.com • October 12, 2011

Dr. Teitelbaum, a well-known fatigue and pain specialist who contracted CFS as a medical student, has researched ME/CFS/FM patients’ nutritional and therapeutic needs for more than 20 years. This article is reproduced with kind permission* from his educational web site at https://www.vitality101.com/

Reprinted with the kind permission of ProHealth: 10/12/11

______________________________________

Treating Low Blood Volume & Decreased Heart Function in CFS & FM

In this important article we will discuss a critical but usually overlooked part of treating Chronic Fatigue Syndrome and fibromyalgia effectively. It can be relatively easy to treat, but is not very glamorous, and is therefore often forgotten.

We will focus on research by Dr. Barry Hurwitz and a team of University of Miami researchers, including Dr. Nancy Klimas, who is wonderful and one of my favorite people in the CFS community… Their [2009] study shows that patients with CFS have:

1. A lower blood volume (basically are dehydrated).

2. Fewer red blood cells to carry oxygen and nutrients (basically anemia, despite normal blood tests).

The study also discusses that although the heart may be smaller in CFS and beats less efficiently, this is likely caused by the dehydration and low blood volume, as opposed to primarily being a heart problem. (More on the details later.)

The good news is that all of these issues can be effectively treated and optimized naturally – which can leave you feeling much better!

THE BOTTOM LINE FIRST

There are several key things that you can do to treat the low blood volume and low blood cell levels that will leave you feeling better:

1. Treat the Dehydration.

Despite your increased thirst and drinking a lot (“like a fish”), most of you are still dehydrated because you’re urinating even more. This occurs for several reasons, including underactive adrenal function and a decrease in antidiuretic hormone (“anti-peeing hormone”), both of which are routinely present in CFS because of the hypothalamic dysfunction (“blowing a fuse”) that we often discuss….

Quick Fixes:

a. Drink more water! Instead of counting glasses of water (an annoying way to spend the rest of your life), check your mouth and lips to see if they are dry. If they are, drink!

b. Eat more salt. Unless you have high blood pressure or heart failure, you need more salt than most people. In fact, many studies have shown that the more salt people eat the longer they live [see sidebar at end of article, “High Salt Intake is Associated with BETTER Health”], and for most people the need to avoid salt has been a problematic medical myth (see six dangerous “Medical Myths“). Use an iodized salt or better yet sea salts… Enjoy salty foods as well.

c. Improve adrenal function. This is discussed at more length in “The Adrenal Gland, and Symptoms of Adrenal Insufficiency,” but a simple way to do this is with an excellent product called Adrenal Stress End.

d. Saline IVs. Clinical experience has also shown that salt water (saline) IVs can be very helpful. The effects are transient though, unless other nutrients are added  – e.g., the Myers’ Cocktails [which are IV vitamin and mineral therapies first conceived in the 1970s by the late John Myers, MD, at Johns Hopkins] administered at holistic physicians’ offices [such as] the Fibromyalgia and Fatigue Centers.

2. Increase Your Body’s Production of Red Blood Cells.

Although treating the infections and hormonal problems we discuss overall in the SHINE Protocol will do this (addressing possible problems with Sleep, Hormones, Infection, Nutrition, and Exercise), below are key things that will help.

a. Treat for low iron – even if your blood tests are normal but modestly low. The best blood test is called a “ferritin” level. Your doctor will say it is normal if it is over 12, but research has shown(2) that in people with chronic fatigue, iron supplementation increased energy dramatically in people with a ferritin under 50 (see Iron Helps Fatigue – Even with Normal Iron Levels and No Anemia) who were not anemic. If the ferritin blood test is under 50, or the iron percent saturation blood test is under 25%, take 1-2 tablets of iron (29 mg with vitamin C) each afternoon or evening on an empty stomach for 4-6 months.

b. Treat for low testosterone and low thyroid levels – despite the normal blood tests. Both of these, especially the testosterone (use only the safe and natural bioidentical forms), increase red blood cell production.

3. Improve Your Heart Function

Though the study discussed in this article notes that the low blood volume and anemia are key, other studies and clinical experience show that nutrients that improve heart function also improve energy in CFS patients. These include:

a. Ribose (Corvalen) 5 gm (1 scoop) 3x day for 3 weeks, then twice a day.

b. Acetyl L-carnitine 500 mg 2x day. [See for example “Long-chain acylcarnitine deficiency in patients with Chronic Fatigue Syndrome,” Journal of Internal Medicine, Jul 2011].

c. The Energy Revitalization System vitamin powder (contains 50 nutrients including B vitamins and magnesium).

d. Coenzyme Q10 at 200 mg daily.

Give the above treatments 6-12 weeks to see the effect. But by one month, most of you will be feeling a lot better with these treatments. In addition, if you have not already done so, do the free Symptom Analysis Program to tailor an overall treatment protocol to your case. Although you do not need to have your blood tests results, if they are available the program will also analyze the more important tests.

WHAT THE UNIVERSITY OF MIAMI STUDY SHOWS

The study(1) looked at 146 people with chronic fatigue syndrome, 30 of whom were very severely affected. It compared them to healthy controls and then factored in how active or sedentary the people were.

People with CFS showed 25% lower heart contractility, so they pumped much less blood.

They then did specialized testing which showed what the person’s total blood volume was and also whether they had enough red blood cells, both of which have been shown to be low in the majority of those with severe CFS.

As all of the above problems have been shown to be common in CFS, the study explored whether there was predominantly a heart problem or whether all of these findings could be explained by dehydration and having too few red blood cells. I would note that, normally, having too few red blood cells would be called being anemic.

Unfortunately, the standard blood tests for anemia compare the amount of blood cells relative to the blood volume. As both are low, the blood count tests come back as normal despite CFS patients in reality being functionally very anemic.

As the study authors note, “The elevated prevalence of low red blood cell volume suggests that the CFS subjects may have an anemia type that goes undetected by standard hematologic evaluations.”

In other words, people with CFS are likely to be anemic despite normal testing (being 6% to 13% lower than optimal, depending on the severity of their CFS).

The role of decreased heart function in CFS has been a major focus of work by Dr. Paul Cheney, MD, PhD, a chronic fatigue syndrome expert who is intimately familiar with the effects of heart problems, as he needed a heart transplant himself. He theorizes (and I am markedly oversimplifying his theory) that heart function decreases as an adaptation to not being able to properly handle the oxygen needed to make energy in CFS.

Chronic disease in general can trigger dehydration and low red blood cell volume, so there are many possible reasons for these occurring in CFS. Deconditioning can also then decrease heart function.

This study was associated with another study looking at whether injections of a prescription blood cell stimulating hormone called
“erythropoietin” would be helpful in CFS, which would naturally lead to some focus towards interpreting the results as being associated with a deficiency of blood cells as opposed to a heart problem. The benefits of erythropoietin treatment were modest relative to the cost and hassle, though, and I think the researchers’ bias is fairly modest.

The authors conclude, “Given these findings, it may be prudent in the clinical setting to perform a direct examination of blood volume status in CFS patients and consider treatment for those with abnormal levels. A blood volume deficit may:

• Impact adversely oxygen delivery and nutrient supply,

• Impair hemodynamic regulation (e.g., blood pressure and heart function),

• And contribute to the exacerbation of fatigue and other CFS symptomatology.”

As their earlier study showed minimal benefit from only increasing the amount of red blood cells using erythropoietin, it again shows the need to use an overall treatment approach to treat all the problems present in CFS.

These include raising red blood cell mass and treating the dehydration, but also treating the underlying infections, adrenal under activity, and other problems that are at the root of these problems.

As we know that most people with CFS will have the dehydration and “anemia despite normal blood testing,” I do not think it is worth the cost of doing these expensive nuclear scans, but instead recommend the simple treatments discussed in the summary above, which we know are helpful in CFS. (Again, these are part of the SHINE Protocol.)

* * * *

SIDEBAR: High Salt Intake is Associated with BETTER Health
Re: “Sodium Intake & Mortality Follow-Up in the Third National Health and Nutrition Examination Survey – NHANES III.”

This study is a fascinating one. It is based on the NHANES data base, which is one of the most respected (if not the most respected) nutritional data bases in the country. What the study showed is the opposite of what we have been led to believe medically.

It showed that the lower the salt intake, the HIGHER the risk of death. Put differently, our advice to people to avoid salt is more likely to be harmful than helpful!

On the other hand, though there was no significant evidence that salt was harmful, the evidence for a low salt diet being harmful was modest, so if people want to avoid salt it probably won’t hurt them too much.

The possibility of a low salt diet being harmful was also likely affected by more people in the low salt diet group having high blood pressure, so it may have been the underlying high blood pressure which caused their higher death risk (i.e., people with high blood pressure were told by their doctors to be on low salt diets, and this could be a “confounding variable” that makes people misinterpret the data. The low salt didn’t kill them, but rather it was their earlier high blood pressure).

Bottom line – Enjoy yourself! Eat the amount of salt that your body wants and don’t worry about it (if you don’t have high blood pressure or heart failure).

The Abstract:
“Sodium Intake and Mortality Follow-Up in the Third National Health and Nutrition Examination Survey – NHANES III.” (The full text article is here – https://pmc.ncbi.nlm.nih.gov/articles/PMC2518033/)

Background: Sodium restriction is commonly recommended as a measure to lower blood pressure and thus reduce cardiovascular disease (CVD) and all cause mortality. However, some studies have observed higher mortality associated with lower sodium intake.

Objective: To test the hypothesis that lower sodium is associated with subsequent higher cardiovascular disease (CVD) and all cause mortality in the Third National Health and Nutrition Examination Survey (NHANES III).

Design: Observational cohort study of mortality subsequent to a baseline survey.

Participants: Representative sample (n=8,699) of non-institutionalized US adults age 30 and older, without history of CVD events, recruited between 1988-1994.

Measurements and Main Results: Dietary sodium and calorie intakes estimated from a single baseline 24-h dietary recall. Vital status and cause of death were obtained from the National Death Index through the year 2000.

Hazard ratio (HR) for CVD mortality of lowest to highest quartile of sodium, adjusted for calories and other CVD risk factors, in a Cox model, was 1.80 (95% CI 1.05, 3.08, p=0.03). [Note: an HR of 1.0 would represent no difference; so a ratio of 1.80 would indicate that individuals in the lowest sodium intake quartile were 80% more likely on average to die of a cardiovascular event than those in the highest sodium intake group.]

Non-significant trends of an inverse association of continuous sodium (per 1,000 mg) intake with CVD and all-cause mortality were observed with a 99% CI of 0.73, 1.06 (p=0.07) and 0.86, 1.04 (p=0.11), respectively, while trends for a direct association were not observed.

Conclusion: Observed associations of lower sodium with higher mortality [all causes] were modest and mostly not statistically significant. However, these findings also suggest that for the general US adult population, higher sodium is unlikely to be independently associated with higher CVD or all-cause mortality.

___

1. Low Blood Volume and Red Blood Cell Mass Study, Abstract: “Chronic fatigue syndrome: Illness severity, sedentary lifestyle, blood volume and evidence of diminished cardiac function,” Barry E. Hurwitz, Nancy G. Klimas, et al. Behavioral Medicine Research Center, University of Miami, Florida. Clinical Science (Lond), Oct 19, 2009.

2. Reference for Iron Study: “Iron supplementation for unexplained fatigue in non-anaemic women: Double blind randomised placebo controlled trial,” F Verdon, et al. BMJ, May 2003.

* Copyright © 2011 by The Annapolis Chronic Fatigue and Fibromyalgia Research Center for Effective CFS/FMS Therapies. All rights reserved.

Disclaimer: These statements have not been evaluated by the FDA. This information and the supplements discussed are not intended to diagnose, prevent, treat or cure any illness, condition or disease. It is very important that you make no change in your healthcare plan or health support regimen without researching and discussing it in collaboration with your professional healthcare team.

“Maggie’s Panic”: When Fibromyalgia & ME/CFS Symptoms Gang Up

Reprinted with the kind permission of ProHealth: April 13, 2011

This case history of a patient with CFS and fibromyalgia, plus panic attacks fueled by the autonomic dysfunction that is common with both, is excerpted from Dr. Bell’s book Faces of CFS – Case Histories of Chronic Fatigue Syndrome,* published in August, 2000. “Maggie’s Panic” illustrates one aspect of the illness he has studied in patients affected by the ‘Lyndonville Outbreak’ over the years.

MAGGIE’S PANIC

I do not think a hidden neurosis or other psychiatric condition was lurking in Maggie’s subconscious. Her panic was organic in nature; it came on as a result of physiologic, not psychiatric, factors.

Maggie came into my office about two years ago. By then, she had been ill with chronic fatigue syndrome (CFS) for ten years. She was fairly classic for the disease: joint and muscle pain; night sweats; a headache that would not end; severe fatigue. Despite the latter, she could barely sleep at night.

Naturally, the doctors she had seen in the past were unable to explain the strange combination of symptoms that seemed to possess her like some demon from a haunted past. Maggie, in fact, had been to so many doctors, including two psychiatrists, that she had lost count.

Doctors grow suspicious when patients tell them they already have seen several doctors for the same problems; they assume such patients are looking for a medical opinion they like, as opposed to a medical diagnosis. This is called, in the trade, “doctor shopping.” Maggie knew she had been typecast as a shopper, but she was searching for a diagnosis that made sense.

The symptoms that distressed Maggie the most had to do with her heart.

If she took a walk, she developed chest pain and become short of breath. Once, she told me, after taking a very long walk, she had seen a doctor the next day. She looked ragged, as if she run a marathon and come in last. Her resting pulse was too fast – 110 beats per minute. She told the doctor that she was afraid she was having a heart attack, but the doctor surprised her with a diagnosis of panic attack, instead. Panic disorder has long been viewed as a bona fide condition in which the patient experiences panic at inappropriate times.

Chest pain and shortness of breath were just part of Maggie’s ‘heart’ symptoms, however.

• She often had episodes when her heart would race. Her heartbeat wasn’t merely rapid, it felt as if her heart was flopping around in her chest, as if she had drunk a gallon of coffee, but she had given up caffeine years ago.

• Her face would flush and her palms would sweat.

• Her lips would quiver, her hands would tremble, and one of her eyelids would twitch.

Most doctors, if not all, would diagnose what I have just described as panic disorder.

But Maggie also suffered from a constellation of symptoms that were diametrically opposed; in fact, they were remarkably akin to the state of being comatose.

• She was exhausted to the point of being unable to walk. She showered seated on a lawn chair because she could not stand, for instance; she slept on the couch in her living room because she was unable, at times, to climb the stairs to her bedroom.

• Another coma-like symptom had to do with the way her intellect was dulled. While driving, she sometimes couldn’t remember whether green meant stop or go. Nor could she recall the names of members of her family, or remember a seven digit telephone number – even if it happened to be her own. She found the dialogue on afternoon soap operas incredibly confusing, like a foreign language. Everyone spoke so fast!

• Her body felt leaden, and curiously toxic; she felt a certain kinship with Chernobyl’s radiation sickness victims.

• Her bowels couldn’t decide between coma or panic; they alternated between constipation and diarrhea.

In truth, her entire body couldn’t decide whether it was in a panic or a coma.

At night, when she awoke drenched in sweat, her heart pounding, it was as if panic was awakening her from her coma. There seemed to be no middle ground. Her doctors told her all these symptoms were ‘due to stress.’ To one such doctor, Maggie commented that, aside from the fact that she had lost her job and her husband, that she was bankrupt, and that she was often too weak to climb the stairs of her house, she really had no stress at all.

Our bodies respond to stressful events with the release of adrenaline from the adrenal glands. Adrenaline activates the body’s primal “fight or flight” response. It is a natural stimulant, resulting in a sudden rush of energy to deal with the crisis at hand. Panic is appropriate in times of danger, and adrenaline will give someone the strength to run, if that’s the best choice, or fight. A cave man confronted by a saber tooth tiger might choose to run; the student faced with final exams might choose to knuckle down and study.

Of course, after the adrenaline rush, we are left exhausted and weak, but the crisis is over and with a little rest we are good as new. This, in fact, is the key difference between panic disorder and CFS. Patients who have panic disorder may have relatively normal activity and energy when there is no panic. CFS patients never achieve a normal level of activity, no matter how much they rest or what measures they take to relieve stress. Take a person with CFS and put them on a sunny beach for a day, and their fatigue will not go away, nor will their panic-like symptoms.

Doctors and researchers have long experienced difficulty differentiating CFS [or the dysregulated autonomics of fibromyalgia (1,2,3)] from simple anxiety.

It is true that many persons with CFS experience anxiety. But because CFS patients tend not to have obvious, diagnosable psychiatric illnesses, I suspect that when panic occurs in CFS patients, the cause is physiological, not psychiatric. Whatever else this disease does to the human brain, it includes agitation in its repertoire.

That first time I evaluated Maggie, I realized her medical history was consistent with both CFS and panic disorder, however. In fact, if I were to follow the strict guidelines that the government has laid down regarding CFS, I would not diagnose Maggie with CFS. That’s because research criteria in use today are designed to create a homogeneous population of CFS patients for research purposes.

From clinical experience, however, Maggie’s tender lymph nodes, sore throat, endless headache, and intellectual difficulties were not consistent with a diagnosis of panic disorder. From a clinical point of view the most accurate diagnosis I could render for Maggie was both panic disorder and CFS.

Maggie didn’t really care about the label; she wanted to get at the basis of her symptoms.

Together, we decided to try some of the newer tests for CFS, tests involving the autonomic nervous system. In particular, we would look at the blood vessels and the heart’s ability to pump blood throughout the body. By the time I met Maggie, I had already learned that many CFS patients had low levels of circulating blood in their bodies, an abnormality sometimes accompanied by pulse and blood pressure changes when standing.

The medical term used for this is “orthostatic intolerance,” meaning, simply enough, a worsening of symptoms when in the upright position.

In many medical illnesses, the patient will feel ill regardless of whether he or she is lying down or standing up. With CFS, patients will say, “I feel so exhausted I have to lie down.” For 15 years, nearly every patient with CFS has said this sentence, and I, as well as most other doctors, have misinterpreted it. No wonder this illness is so poorly understood. People should not be tired from standing up for 15 minutes.

We have concentrated on the word “exhausted,” but the key words are, in fact, “lie down.”

The terms “fatigue” or “exhausted” don’t even really describe the unpleasant sensation experienced. “Collapse” is more accurate. What the patient with CFS is really saying is “If I don’t lie down, I am going to collapse.” Medically, the appropriate term is “pre-syncopal,” meaning the state which occurs prior to fainting.

Maggie agreed to allow me to test her orthostatic tolerance, her ability to function during quiet standing.

During a physical exam, she had two abnormalities:

• Fibromyalgia tender points in her muscles

• And difficulty maintaining her balance standing with her eyes closed, a common finding in patients with CFS.

The practical expression of this finding is that patients with CFS are frequently unable to stand for periods in a hot shower. The heat of the water in the shower makes standing more difficult than normal, and often patients will have to go to bed after a simple shower. Sometimes, persons with CFS will put a chair in the shower even though they may be able to walk around the kitchen for ten minutes. A curious, but important detail that Maggie related, implying that heat somehow worsened the process.

The first test we did was very simple, a test of concentration done on two different days, once while standing for 15 minutes and once after lying down for the same length of time.

One of the most prominent symptoms of CFS is the cognitive impairment. Patients will have difficulty with confusion, short term memory, doing simple calculations, and remembering names or telephone numbers. Sometimes this is so severe that concern is raised about dementia or senility. The hardest thing for a patient with CFS is “double tasking.”

My son has amazing powers of concentration. He can be in his room doing his homework, listening to rock-and-roll music while the TV, without sound, shows a football game. I made many vain attempts to inform him that it is not possible to do his homework that way, but his grades were good, and studying this way seemed to do little harm. He was able to “multiple task,” just like I do when I talk on the car phone, drive, and find a quarter for the toll booth, all at the same time. For my son, he probably used 80% of his brain studying, 19% enjoying the music, and 1% watching the football game. Most shows on TV, the sitcoms, can be enjoyed with even less dedicated brain function.

Double tasking is one of the first things to go in CFS.

The test we gave to Maggie was the coding test of  the WISC, a standard intelligence test. In this test, a series of simple codes are made for numbers between 0 and 9, the code printed at the top of the page. The test involves finding, or remembering, the codes for a list of numbers, and scoring is done by adding up the correct coding accomplished in two minutes. It is an annoying little test.

After lying down, Maggie did the test, getting 55 right in two minutes, a normal amount. A week later we repeated the test after standing, and she was able to get only 40 correct, a 20% drop. We have been testing this with healthy persons, and found that, in general, they do as well standing as after lying down.

Maggie’s cognitive problems are related to the position she is in before the test. When horizontal, she does well; after standing, she is dull as a melon. This correlates to another curious detail often found in the history taking of someone with CFS – they read lying down. Most healthy persons prefer to read sitting up.

We measured Maggie’s circulating blood volume at a nearby hospital, and like 80% of our CFS patients, she was low, or as she would later say, “down a quart.”

This finding seems to mesh with the difficulty standing; gravity makes it difficult for blood to get up to the brain, and if the circulating blood volume is low, it should affect brain blood flow. And the mechanism of CFS may be that simple: decreased blood flow to the brain. We don’t know if animals can get CFS, but if they do, giraffes would be in big trouble.

The next test was the most exciting for me, the most unpleasant for Maggie. We call it “orthostatic testing” and it can be done in any doctors office.

It is a simple test, perfected by Dr. David Streeten (4), and described in Andrea Thompson’s case. The patient lies down for 10 minutes during which the pulse and blood pressure are taken. Then during a half hour of quiet standing the pulse and blood pressure are measures every five minutes along with observations of what the patient is experiencing.

Maggie’s blood pressure and pulse were normal while lying down, and she was feeling relatively well – it was a good day for her. We measured the amount of adrenaline in her blood while lying down and it came back at 350, a normal level. The first ten minutes standing were not bad for Maggie, although she started feeling tired. Then she described pain in her legs, lightheadedness, and spiraling fatigue. Her palms were sweaty, and I saw her grow visibly pale. Most significantly of all, she became agitated, and, eventually, she became panicked.

The pulse and blood pressure measurements began to change. When Maggie said she could no longer stand, we terminated the test, I did not want her to pass out on the floor. Her pulse had risen to 140 beats per minute, 80 more than when she had started, and her blood pressure had skyrocketed, almost to levels that could cause a stroke.

As soon as Maggie lay down, we drew a second blood sample to measure her adrenaline again. I also gave her an infusion of saline water. Normally, saline is the last thing you want to give someone with high blood pressure, but I already knew Maggie had abnormally low circulating blood volume.

The elevation of her blood pressure had to be due to a constriction of the blood vessels, a compensation mechanism that would help circulate the blood to her brain. The fast pulse reflected the same problem: Her autonomic nervous system was trying to make her heart beat faster in order to circulate blood.

While standing, Maggie began to fall apart because her brain was deprived of blood.

A healthy person has several compensatory mechanisms that automatically keep blood flowing to the brain indefinitely. Maggie might look healthy to a casual observer, and the private disability company she had paid into for many years prior to becoming ill said that she was just fine.

But imagine Maggie trying to work an eight hour day when she had such dramatic changes in pulse and blood pressure after just 20 minutes standing. I would definitely not want her to be my bank teller trying to make change after standing for two hours.

Maggie’s compensatory mechanisms were impaired. All but one, that is: adrenaline production.

The body produces adrenaline to compensate for impaired blood flow to the brain. In fact, it is one of the body’s most effective ways of improving circulation, which is why it is called the “fight or flight” mechanism.

Perhaps the most significant finding we made that day had to do with Maggie’s adrenaline. Her adrenaline level had risen to 1450, way above normal, when she had been forced to stand for 20 minutes. Maggie’s body was pumping out adrenaline like mad just to compensate for the crisis of quiet standing.

Adrenaline has one drawback: It causes anxiety.

I believe now that Maggie’s panic was simply due to elevation of her adrenaline levels in an attempt to compensate for impaired blood flow to the brain. I do not think a hidden neurosis or other psychiatric condition was lurking in her subconscious. Her panic was organic in nature; it came on as a result of physiologic, not psychiatric, factors. Panic is appropriate during a crisis, but not during quiet standing.

The surge of adrenaline has several drawbacks. First, it doesn’t work very well. If it had, Maggie would feel wonderful, like the burst of energy after having a cup of coffee in the morning after a good night’s rest. It may be that the adrenaline keeps her up longer, but the price is fatigue. A healthy person will notice that after a crisis, a near car accident for example, the surge of adrenaline is followed by profound exhaustion. Chronic stress will leave a person drained and tired, but recovery occurs quickly once the stress is removed and good rest is supplied.

Maggie’s fatigue is due to a combination of decreased blood flow to the brain and the surge of adrenaline her body produces to attempt to remedy the problem.

Suddenly, there were several medical diagnoses I could give Maggie.

Technically speaking, she had chronic fatigue syndrome, fibromyalgia pain and tender points, idiopathic hypovolemia (decreased blood volume), postural orthostatic tachycardia, orthostatic narrowing of the pulse pressure, orthostatic diastolic hypertension, and hyperadrenergic orthostatic intolerance.

Maggie was not displeased; literally overnight, she had gone from being a hypochondriac to having seven medical diagnoses.

Research into blood volume and brain blood flow is in its infancy. Nevertheless, while we are still in the dark as to what initiates these problems, breaking CFS down into its many parts may allow us to develop specific diagnostic tests for the disease.

Moreover, Maggie’s testing results inspire theoretical treatment options. If we could somehow increase blood flow to the brain and deliver more oxygen to brain tissue, the symptoms of impending collapse should improve. The need for the adrenaline surge would be removed, so the postadrenaline exhaustion would also disappear. In concept, that is.

The co-existence in CFS patients of simultaneous coma and panic symptoms is no longer paradoxical.

Doctors and researchers who assume panic disorder is caused by psychiatric problems exclusively have been looking at the phenomenon in an overly simplistic way. The same chemical mediators that are present in emotionally stressful situations are also the same chemical mediators that help circulate the blood. A test would be to find a way to improve the blood circulation in the brain.

We started with a drug to expand her blood volume, and Maggie’s response to treatment made me so excited that my socks started rolling up and down all by themselves.

Peter Rowe and his colleagues at Johns Hopkins made an important discovery in 1996 after discovering that patients with CFS would faint when tilted upright on a tilt table. They treated their patients with a drug called fludrocortisone (Florinef™), which works by increasing salt and water retention by the body, thus raising blood volume.

I had tried Florinef in many of my patients, and it improved their symptoms about one-third to one-half the time. In my experience, adolescents and those with milder illness responded best to this treatment. The drug helped Maggie: her rapid pulse slowed down, her sleep improved, and she felt slightly more energy. Her panic nearly disappeared.

The concept that a presumably psychiatric symptom – panic – would be helped by a drug which increases circulating blood volume is hard to believe. But it happened to Maggie. Her panic was clearly caused by CFS and its concomitant blood volume deficits, not the other way around. I was encouraged by these changes, but my socks had not yet started rolling, the surprise was yet to come.

Maggie and I talked almost every day during this trial, and we decided to push the therapy a little further by adding salt tablets, hopefully to augment the response.

Two days after adding salt tablets, Maggie returned to “normal.”

At first, I didn’t know what Maggie meant by “normal.” Did she feel a bit better? No, she was reporting complete recovery, normal for the first time in ten years. It was as sudden as a switch being thrown; she described her transformation as “awakening from a dream.” Her thinking was crystal clear. She walked for two miles that first day, smelling the flowers of spring. The whole feeling of illness, the malaise, was gone.

Unfortunately, her recovery was brief. Thirty-six hours later, she began slipping back to her former state, minus the panic, and she has remained in that particular jail cell since then.

We have tried 20 different treatments, raising and lowering doses of this and that, but she has not regained her freedom. In retrospect, the memory of 36 hours of freedom remains a cruel reminder of how nice it feels to be healthy.

The importance of Maggie’s experience to me is a confirmation of a long held belief that CFS is a reversible state, even after ten years.

Not just treatable by reducing some of the symptoms, but reversible. Her return to health was short lived, but it occurred. If she had permanent damage to her brain, I do not think the 36 hours would have been possible.

What is so frustrating is the fact that this state could not be maintained, even though we tried treatments that pushed so much blood into her brain that her skull was ready to explode. Maggie has been a good sport about all of this. Each treatment attempt was discussed in detail and she was eager to take the steps.

While disappointed that we have not been successfuI I see the problem a little differently now. By expanding blood volume it is possible to make some improvements, but not all the time. Even with Maggie’s dramatic 36 hours, the response cannot be maintained even if the blood volume is returned to normal or even elevated levels.

The problem must be in the blood vessels themselves. They must be constricted so tight in the brain that little blood gets through. Perhaps it is one of the hormones that constricts blood vessels. Perhaps an infection of the blood vessels. Perhaps it is an excessive sensitivity of the blood vessels to adrenaline.

Hopefully, this story will soon have a new and more encouraging ending. CFS is a devastating physiologic process that undermines the body’s energy and the brain’s cognitive ability, but I believe that full recovery will someday be possible.

We await the next step, the step that will make Maggie’s precious 36 hours stretch into days, months and years. There is so much to study in this illness, and so much to be gained. Science needs to recognize the importance of CFS, embrace its difficult paradoxes, and get to work.

• CFS is not an isolated, rare illness nor is it an illness behavior for lazy people.

• The consequences of this illness weigh heavily on not only the victim, but also on family, community and society.

• Its tentacles seem to reach across boundaries, blurring the lines between other neurological and immunological disorders.

CFS, and the patients who suffer from it, have a great deal to teach those of us who have made medicine our life. Once researchers unravel the physiologic mechanisms of this illness, the discoveries will help unravel basic mechanisms of unnumbered other diseases.

– Dr. David S Bell, MD, Lyndonville, New York, August 15, 2000

____

* This article is excerpted with kind permission from Dr. Bell’s classic book Faces of CFS – Case Histories of Chronic Fatigue Syndrome; © David S Bell, MD, 2000.

The Pall Protocol for Treating CFS/ME

Dr. Martin Pall’s NO/ONOO– (“No! Oh, no!”) hypothesis is probably the most comprehensive explanation of cellular dysregulation in CFS and other oxidative stress illnesses. His model proposes that the chronic stage of CFS is driven by a vicious cycle of oxidative stress, in which the basic mechanisms that are meant to control pathogens don’t turn off. The result is oxidants run amok, creating havoc in the cell’s energy cycles, and increasing inflammation.

The protocol described here was originally put together by Dr. Pall and by Dr. Grace Ziem. It is based on antioxidant treatments which break the vicious cycle of oxidative stress as well as other agents that act to lower other parts of the cycle, such as lowering inflammatory responses, improving mitochondrial function and lowering excessive NMDA activity. However, taking large quantities of single antioxidants can actually increase oxidative stress. Once antioxidants such as tocopherols (vitamin E), vitamin C, and flavonoids react with free radicals, these antioxidants are themselves converted into free radicals. Other antioxidants are then needed to neutralize those newly formed free radicals. Therefore, a wide variety of antioxidants is optimal.

PLEASE NOTE: Dr. Pall emphasizes that he is a Ph.D., not an M.D., and none of these therapies should be viewed as medical advice.

Below is a list of Dr. Pall’s therapies. More detailed information follows.

  1. Nebulized reduced glutathione
  2. Nebulized inhaled hydroxocobalamin
  3. Mixed natural tocopherols
  4. Buffered C
  5. Magnesium, as malate
  6. Four flavonoids: gingko, cranberry extract, silymarin and bilberry
  7. Selenium, as selenium-grown yeast
  8. CoQ10
  9. Folic acid
  10. Carotenoids including lycopene, lutein and B carotene
  11. Alpha lipoic acid
  12. Zinc (modest dose), manganese (low dose), copper (low dose)
  13. Vitamin B6, as pyridoxal phosphate
  14. Riboflavin 5′-phosphate
  15. Betaine (trimethylglycine)
  16. Acetyl-carnitine
  17. Taurine

Detailed antioxidant protocol:

Vitamin C. Pall suggests doses on the order of 500 to 1000 mg/day, taken several times per day. Vitamin C can act to regenerate tetrahydrobiopterin (BH4) and, therefore, may act to lower nitric oxide synthase (NOS) uncoupling, and high doses of vitamin C can be useful in scavenging peroxynitrite (ONOO–), the most central element in his NO/ONOO– cycle hypothesis.

CoQ10. CoQ10 has been used in a number of diseases to improve mitochondrial function. It scavenges free radicals, protects against loss of mitochondrial respiratory function, increases energy metabolism, and down regulates NMDA activity. Take early in the day.

Magnesium. This mineral lowers NMDA activity, reducing excitotoxicity. Dr. Pall believes that “magnesium is one of the most promising agents for treatment of multisystem diseases, but, like other such agents, it produces modest responses and may best be used in a complex, combination therapy.”

Selenium. Selenium is considered an antioxidant because certain proteins that contain selenium have antioxidant properties. Selenium occurs in glutathione peroxidases, enzymes that eliminate peroxide in cells. Selenium is also essential in making T3, the most active form of thyroid hormone. The best form of selenium is selenomethionine, which is a selenium-grown yeast. (For those who are yeast-sensitive, there are non-yeast forms.)

Carotenoids. These are plant pigments which are quite active in scavenging free radicals. Lycopene is more active than beta-carotene as a peroxynitrite scavenger. Lutein and zeaxanthin, two carotenoids, may also have special roles as antioxidants because of the way they insert into biological membranes.

Flavonoids. Anthocyanidins, which are found in purple plants, lower inflammatory activity, act as potent chain-breaking antioxidants, and regenerate other chain-breaking antioxidants after they have been converted to free radicals. Flavonoids also act as chelators for free iron, protecting cells from oxidative damage. Many flavonoids are soluble in both water and lipids. Flavonoids from green tea, citrus, grape seed extract, gingko, soy, olive, hawthorn, blueberry, and purple rice are effective antioxidants. Silymarin scavenges peroxynitrite, and increases the synthesis of SOD (superoxide dismutase), which makes it especially important. Flavonoids are rapidly absorbed in foods, and are quickly excreted through the kidneys, so they need to be eaten (or taken) throughout the day.

Acetyl-L-carnitine. Carnitine transports fatty acids into mitochondria, and is therefore essential for providing cellular energy. Acetyl-L-carnitine is more effective than L-carnitine because most oral L-carnitine ends up being excreted by the kidneys before it can be transported through the blood-brain barrier. Acetyl-L-carnitine is transported more efficiently. Recently, it has been shown that acetyl-L-carnitine lowers excessive NMDA activity and this may well be more important than the effects on mitochondrial function for lowering the NO/ONOO– cycle.

Reductive Stress Agents. Reductive stress causes oxidative stress. Methyl groups – SAMe, betaine, and carnitine – act as protective agents. Dr. Pall’s preference for a methylated compound is betaine (TMG.) It is cheaper and more stable than SAMe.

Hydroxocobalamin form of B12. B12 is a potent nitric oxide scavenger, but it is difficult to absorb. Oral absorption of B12 is limited by intrinsic factor. [Independent of intrinsic factor, the absorption rate of B12 is less than 1% of the total amount ingested.] Hydroxocobalamin taken as a nasal spray or injection is more effective.

Folate (folic acid). Reduced folate decreases uncoupling of NOS activity. Reduced folate in the form of 5-methyltetrahydrofolate (5-MTHF) is a potent scavenger of peroxynitrite and may well turn out to be among the most useful agents for lowering the NO/ONOO– cycle. Optimal dosage may well vary among different individuals but, in general, it should be taken along with quite a bit of vitamin C (at least 500 mg and preferably perhaps twice this amount). The reaction between peroxynitrite and 5-MTHF is important not only because it can be used to lower peroxynitrite levels. It is also important because in NO/ONOO– diseases, elevated peroxynitrite will act to lower the levels of 5-MTHF, lowering methylation cycle activity, and will also act to lower all reduced folates in the body. In this way, lowered methylation activity may be caused by the NO/ONOO– cycle.

B6, as P5P. B6 minimizes neurotoxicity. The best form is pyridoxine phosphate (P5P).

Riboflavin. Riboflavin is important for the production of reduced glutathione. It is also useful in the treatment of migraine.

Alpha Lipoic Acid (ALA) scavenges free radicals. As an added benefit, it can regenerate other antioxidants by reducing oxidized and free radical forms of glutathione, tocopherols, vitamin C and flavonoids. It can maintain glutathione pools by turning oxidized glutathione into its active form, reduced glutathione. ALA can cross the blood-brain barrier, making it an effective tool for reducing damage due to oxidative stress in the brain.

Zinc, Manganese and Copper. These minerals are components of superoxide dismutases (SOD), the enzymes that convert the oxidant superoxide into hydrogen peroxide and oxygen. Zinc, copper and manganese deficiencies can produce oxidative stress, part of which may be due to the lowered ability to produce SODs. Doses of these metals can be tricky. Excessive levels of copper and manganese can themselves produce oxidative stress. Excessive zinc lowers copper levels. Dr. Pall suggests “modest levels.”

Taurine is an unusual amino acid, because it is an antioxidant as well as a neurotransmitter. Taurine acts to stimulate the synthesis of GABA, and is transported easily across the blood-brain barrier, allowing it to work in the brain. Taurine stimulates several inhibitory receptors, leading to lowered NMDA activity. It also acts to lower intracellular calcium levels, thus lowering NO synthesis.

Long-chain omega-3 fatty acids. Polyunsaturated fatty acids (PUFAs) are more susceptible to lipid peroxidation than are other fatty acids, and consequently they tend to be depleted whenever there is oxidative stress. Fish oil, borage oil and flaxseed oil are sources of long-chain omega-3 fatty acids.

Curcumin, honokiol (from magnolia), cat’s claw, vinpocetine and feverfew all reduce inflammation by lowering NF-kappaB activity, as do a number of conventional pharmaceuticals.

Vitamin E should not be taken as synthetic alpha-tocopherol, which is the most commonly taken form, Pall argues. Rather, it should be taken as relatively high doses of gamma-tocopherol and tocotrienols with modest amounts of natural alpha-tocopherol. These other forms of vitamin E have important functions, such as lowering inflammation, scavenging an important breakdown product of peroxynitrite, lowering excessive NMDA activity and improving mitochondrial function, all important for lowering NO/ONOO– cycle diseases.

Algal supplements. Both chlorella and blue-green algae are rich in antioxidants. Blue-green algae contain phycocyanin, which is a potent free radical scavenger.

FURTHER READING:

Pall, Martin. Explaining “Unexplained Illnesses”: Disease Paradigm for Chronic Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic Stress Disorder, Gulf War Syndrome and Others. New York: Harrington Park Press, trade division of Haworth Press, Inc. 2007.

This book is technical, but well worth reading. Dr. Pall has made a remarkable contribution to the study of “unexplained illnesses.”

“How Can We Cure NO/ONOO– Cycle Diseases: Approaches to Curing Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, Fibromyalgia, Multiple Chemical Sensitivity, Gulf War Syndrome and Possibly Many Others.” Martin Pall. Townsend Letter. Feb/March 2010.

Excellent paper by Martin Pall on agents that lower parts of the NO/ONOO? cycle. Contains detailed information on protocols and potential therapeutic agents. 

Martin Pall – MEPedia’s comprehensive page on Dr. Pall includes publications, talks, interviews, papers, and more.

Antioxidant Suggestions from Dr. Martin Pall, Ph.D.  Tables of supplements recommended by Dr. Pall, along with mechanisms and comments.


Micronutrition as a Therapeutic Strategy for Mitochondrial Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Narrative Review

Abstract:

Fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are chronic multisystem disorders characterized by persistent fatigue, pain, cognitive dysfunction, sleep disturbances, and reduced quality of life. Increasing evidence implicates mitochondrial dysfunction, oxidative and nitrosative stress, immune dysregulation, and altered redox and nicotinamide adenine dinucleotide (NAD+) metabolism as interconnected mechanisms contributing to fatigue, although the strength of evidence varies across these pathways. Micronutrients are essential components of mitochondrial bioenergetics, antioxidant defense, and immune-metabolic regulation.

This narrative review critically examines the mechanistic and clinical evidence supporting mitochondrial-oriented micronutritional interventions in fibromyalgia and ME/CFS, including NAD+ precursors, B-complex vitamins, magnesium, coenzyme Q10, alpha-lipoic acid, GlyNAC, L-carnitine, pyrroloquinoline quinone, taurine, and creatine. Mechanistic plausibility is distinguished from clinical efficacy, as disease-specific randomized controlled evidence remains limited for several interventions. We further discuss biomarkers, metabolic phenotyping, and precision nutrition within a systems-based micronutrition framework.

Finally, we present the rationale for a future randomized, double-blind, placebo-controlled trial in fibromyalgia patients with clinically significant fatigue, which is planned for 2027, subject to ethics approval and prospective registration, as a strategy for future clinical validation.

Source: Abanades S, Fernández I, Capdevila N, Cardona F. Micronutrition as a Therapeutic Strategy for Mitochondrial Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Narrative Review. Nutrients. 2026 Aug 19;18(16):2702. doi: 10.3390/nu18162702. PMID: 42654282. https://www.mdpi.com/2072-6643/18/16/2702 (Full text)

Targeting Bioenergetic, Redox and Prostaglandin Pathways in Long COVID-Associated Post-Exertional Malaise and Brain Fog: A Nutraceutical Translational Hypothesis

Abstract:

Post-exertional malaise (PEM) and cognitive dysfunction (hereafter “cognitive dysfunction”, including the patient-reported syndrome often described as “brain fog”) are among the most disabling features of Long COVID; yet, approved disease-modifying treatments remain lacking. Emerging evidence implicates interacting disturbances in mitochondrial bioenergetics, redox regulation and neurovascular inflammation, although much of the supporting evidence remains indirect and derives from acute COVID-19, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), primary mitochondrial disease, inflammatory biology and mechanistic pharmacology rather than from direct Long COVID intervention trials.

This hypothesis-generating narrative review develops a mechanism-based translational framework: that a pathway-targeted nutraceutical programme may modulate selected elements of these three axes, subject to prior demonstration of formulation quality, pharmacokinetic feasibility, target engagement and safety. Candidate modules comprise coenzyme Q10 and alpha-lipoic acid for bioenergetic/redox support; selenium, sulforaphane and resveratrol for Nrf2-thioredoxin-related redox regulation; and Boswellia serrata, luteolin and eicosapentaenoic acid for putative prostaglandin/resolution-pathway modulation. Sonlicromanol provides a conceptual mechanistic precedent for combined redox and prostaglandin-directed pharmacology, but it is not considered pharmacologically equivalent to an eight-agent nutraceutical combination.

We summarise the mechanistic rationale, distinguish direct from indirect evidence, define qualitative evidence-grading criteria, outline safety and interaction considerations, and propose a staged translational research programme. This framework is intended to generate falsifiable hypotheses for future Long COVID studies, not to imply established clinical efficacy.

Source: Praet SFE. Targeting Bioenergetic, Redox and Prostaglandin Pathways in Long COVID-Associated Post-Exertional Malaise and Brain Fog: A Nutraceutical Translational Hypothesis. Nutrients. 2026 Aug 13;18(16):2650. doi: 10.3390/nu18162650. PMID: 42654231. https://www.mdpi.com/2072-6643/18/16/2650 (Full text)

Molecular hydrogen as a treatment for ME/CFS: a mini-review of clinical evidence and mechanistic rationale

Abstract:

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating multisystem illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and autonomic dysfunction, yet it currently lacks FDA-approved treatments. Molecular hydrogen (H2), administered primarily as hydrogen-rich water (HRW), has emerged as a potential therapeutic candidate due to its selective antioxidant effects, anti-inflammatory activity, and support of mitochondrial and cellular homeostasis. These mechanisms align with several biological abnormalities implicated in ME/CFS, including oxidative stress, chronic inflammation, and impaired energy metabolism. This narrative mini-review summarizes mechanistic evidence relevant to ME/CFS and evaluates three developmental clinical studies of HRW in this population.

Although early trials are small and methodologically limited, moderate-dose HRW consumed over extended durations has demonstrated feasibility and preliminary benefits in reducing fatigue and improving physical function, with generally mild side effects. Overlapping findings in Long COVID further suggest potential applicability across related post-viral fatigue conditions. Key limitations include small sample sizes, reliance on self-report outcomes, and the absence of objective biomarkers.

Future research should prioritize larger, rigorously controlled trials incorporating remote biometric and biochemical assessments to clarify mechanisms of action and identify responsive subgroups. Overall, molecular hydrogen represents a promising, low-burden adjunctive therapy warranting further investigation in ME/CFS.

Source:Friedberg F and LeBaron TW (2026) Molecular hydrogen as a treatment for ME/CFS: a mini-review of clinical evidence and mechanistic rationale. Front. Med. 13:1760210. doi: 10.3389/fmed.2026.1760210 https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1760210/full (Full text)

A Continuous Oral Regimen of High-Dose Cromolyn Sodium Is Effective for Some Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients With Mast Cell Activation Syndrome

Abstract:

Our clinical experience in the last four years using oral cromolyn in patients with mast cell activation syndrome (MCAS) suggests that a continuous oral regimen of high-dose cromolyn may enhance compliance with the medication. The five patients described in this retrospective case series were given instructions to take oral cromolyn using a continuous dosing regimen, placing the entire day’s dose in an opaque bottle that is then filled with water, and sipping the solution throughout the day. If a conventional maximum dose of eight vials daily (800 mg) was tolerated but ineffective after a week, the patients were instructed to increase to 1600-2400 mg daily until reaching an optimal effect.

We report that a cromolyn dose of 1600-2400 mg daily, administered using the continuous oral dosing regimen during the day, was effective in controlling signs and symptoms of mast cell activation. All five patients benefitted from a dose of cromolyn that is higher than usual and customary recommendations, but within the safety guidelines of the original Food and Drug Administration (FDA) application. The continuous oral regimen has some theoretical advantages over four discrete doses per day, though further study is needed.

Source: Christoforou ME, van Campen LC, Visser FC, Lee CK, Lemmon SL, Rowe PC, Azola AM. A Continuous Oral Regimen of High-Dose Cromolyn Sodium Is Effective for Some Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients With Mast Cell Activation Syndrome. Cureus. 2026 Jan 22;18(1):e102064. doi: 10.7759/cureus.102064. PMID: 41728426; PMCID: PMC12924640. https://pmc.ncbi.nlm.nih.gov/articles/PMC12924640/ (Full text)

Vitamin D in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After COVID-19 or Vaccination: A Randomized Controlled Trial

Abstract:

Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) can develop as post-vaccination syndrome (PVS) or Post-Acute Sequelae of SARS-CoV-2 infection (PASC). In our prior retrospective study, most patients with PVS who developed ME/CFS had vitamin D insufficiency or deficiency. We evaluated the efficacy of vitamin D replacement therapy guidance for ME/CFS symptom improvement in patients with vitamin D insufficiency or deficiency.

Methods: This open-label randomized controlled trial enrolled 91 participants with ME/CFS as PVS or PASC and serum 25(OH) vitamin D < 30 ng/mL across five clinical sites. Participants were randomized 1:1 to intervention (active vitamin D preparation plus vitamin D replacement therapy guidance: 25 μg daily supplementation, dietary counseling, sun exposure, and exercise) or control (active vitamin D preparation alone) for 12 weeks. The primary endpoint was the change in ME/CFS symptom count from screening to Week 12.

Results: Mean symptom change was -6.7 in the intervention group versus -1.2 in the control group (between-group difference -5.6; 95% CI: -7.2, -3.9; p < 0.001). Serum 25(OH) vitamin D improved from 18.6 to 27.1 ng/mL in the intervention group, while the control group showed a decreasing trend (between-group difference 10.2 ng/mL; 95% CI: 7.9, 12.5). Achievement of <8 symptoms (i.e., no longer meeting ME/CFS diagnostic criteria) was significantly higher in the intervention group, with 16 participants achieving this threshold compared to 1 in the control group (p < 0.001). Subgroup analyses showed consistent benefit in both PVS (n = 56) and PASC (n = 29) cohorts.

Conclusions: Vitamin D replacement therapy guidance significantly reduced ME/CFS symptoms along with improvement of serum 25(OH) vitamin D levels in patients with vitamin D insufficiency or deficiency who developed ME/CFS as PVS or PASC.

Source: Kodama S, Nakata M, Konishi N, Yoshino M, Fujisawa A, Naganuma M, Kobayashi Y, Hirai Y, Kitagawa A, Miyokawa M, Mishima R, Teramukai S, Fukushima M. Vitamin D in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome After COVID-19 or Vaccination: A Randomized Controlled Trial. Nutrients. 2026 Feb 3;18(3):521. doi: 10.3390/nu18030521. PMID: 41683343. https://www.mdpi.com/2072-6643/18/3/521 (Full text)

Potential application of brain-gut axis-based treatments in Long COVID and ME/CFS: a case-based systematic review

Abstract:

Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID share clinical features including persistent fatigue, post-exertional malaise (PEM), and gastrointestinal (GI) dysfunction. Growing evidence implicates brain-gut axis dysregulation, characterized by dysbiosis, neuroinflammation within the central nervous system (CNS), increased intestinal permeability, and microbial translocation in their pathophysiology. However, therapeutic strategies targeting these pathways remain poorly defined.

Methods: We report a case of post-COVID ME/CFS successfully treated with electroacupuncture (EA)-based deep peroneal nerve stimulation which was employed to potentiate the vagal reflex. Fatigue trajectories were assessed using the Multidimensional Fatigue Inventory over 12 weeks. Based on the case, a systematic review of randomized controlled trials (RCTs) evaluating brain-gut axis-modulating interventions in ME/CFS or Long COVID was conducted.

Results: The patient exhibited a significant reduction in total fatigue, with early improvements in motivation and mental fatigue, and delayed improvement in physical fatigue following transient systemic symptom flares. Across included RCTs (n = 8, 790 participants), four investigated gut microbiome-modulating therapies and four employed nerve stimulation. Synbiotic and herbal interventions demonstrated benefits for fatigue or PEM, accompanied by alterations in specific bacterial populations or CNS metabolisms. Regarding nerve stimulation, transcranial direct current stimulation (tDCS) combined with exercise program improved fatigue, whereas standalone tDCS, auricular or peripheral TENS showed limited efficacy.

Conclusion: Brain-gut axis-based interventions may alleviate fatigue in ME/CFS and Long COVID by potentially modulating neuroinflammation, restoring microbiome balance, and improving epithelial barrier function. EA-based vagal stimulation represents a feasible option for patients with severe or treatment-resistant symptoms. Larger mechanistic studies and rigorously designed RCTs are needed to establish therapeutic targets and optimize intervention strategies.

Source: Kim DY, Youn J, Kang N, Cho SI, Ha IH. Potential application of brain-gut axis-based treatments in Long COVID and ME/CFS: a case-based systematic review. J Transl Med. 2026 Feb 10. doi: 10.1186/s12967-026-07807-w. Epub ahead of print. PMID: 41668172. https://link.springer.com/article/10.1186/s12967-026-07807-w (Full text available as PDF file)

No consistent evidence for the anti-inflammatory effect of vagus nerve stimulation in humans: A systematic review and meta-analysis

Abstract

Vagus nerve stimulation (VNS) has been identified as an innovative immunosuppressive treatment strategy in rodent studies. However, its’ clinical potential is still unclear. Therefore, we aimed to assess whether VNS can reduce inflammatory proteins and/or immune cells in humans, through a pre-registered systematic review and meta-analysis according to PRISMA guidelines. The databases Cochrane, Pubmed and World of Knowledge were searched in duplicate up to the 3rd of March 2022 and publications from identified clinical trial registrations were identified until 20th of August 2023. Studies were included if they provided peer-reviewed data for humans who received VNS as short-term (<=1 day) or long-term (>=2 days-365 days) stimulation and reported at least one cytokine or immune cell after treatment.

Screening of title, abstract, full text, and data extraction was performed in duplicate by two independent reviewers. Data were pooled using a random-effects model and meta-regression was performed for moderating factors. Reporting bias was assessed. The standardized mean difference (Hedge’s g) was used to indicate overall differences of cytokine data (mean and standard deviation or median and interquartile range at the study level) to test our a-priori hypothesis.

The systematic review of 36 studies with 1135 participants (355 receiving a control/sham condition and 780 receiving VNS) revealed anti-inflammatory effects of VNS for cytokines in several reports, albeit often in subgroup analyses, but our meta-analyses of 26 studies did not confirm these findings. Although most cytokines were numerically reduced, the reduction did not reach statistical significance after VNS: not in the between-group comparisons (short-term: TNF-α: g = -0.21, p = 0.359; IL-6: g = -0.94, p = 0.112; long-term: TNF-α: g = -0.13, p = 0.196; IL-6: g = -0.67, p = 0.306); nor in the within-study designs (short-term: TNF-α: g = -0.45, p = 0.630; IL-6: g = 0.28, p = 0.840; TNF-α: g = -0.53, p = 0.297; IL-6:g = -0.02, p = 0.954). Only the subgroup analysis of 4 long-term studies with acute inflammation was significant: VNS decreased CRP significantly more than sham stimulation. Additional subgroup analyses including stimulation duration, stimulation method (invasive/non-invasive), immune stimulation, and study quality did not alter results. However, heterogeneity was high, and most studies had poor to fair quality. Given the low number of studies for each disease, a disease-specific analysis was not possible.

In conclusion, while numeric effects were reported in individual studies, the current evidence does not substantiate the claim that VNS impacts inflammatory cytokines in humans. However, it may be beneficial during acute inflammatory events. To assess its full potential, high-quality studies and technological advances are required.

Source: Schiweck C, Sausmekat S, Zhao T, Jacobsen L, Reif A, Edwin Thanarajah S. No consistent evidence for the anti-inflammatory effect of vagus nerve stimulation in humans: A systematic review and meta-analysis. Brain Behav Immun. 2024 Feb;116:237-258. doi: 10.1016/j.bbi.2023.12.008. Epub 2023 Dec 7. PMID: 38070618. https://www.sciencedirect.com/science/article/abs/pii/S0889159123003793